Clinical trials: Imatinib Therapy Response
Chronic Myeloid Leukemia
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Research Hypothesis: Treatment with dasatinib 100 mg QD is superior to imatinib 600 mg QD in terms of complete cytogenetic response (CCyR) in chronic phase (CP) Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia…
- Trial name
- NCT00854841
- Testing
- Dasatinib and Imatinib
- Sponsor
- Pusan National University Hospital
Chronic Myelogenous Leukemia - Chronic Phase
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for…
- Trial name
- ASC4REAL-2 (NCT07091019)
- Testing
- TKIs
- Where
- 17 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Myeloid Leukemia, Chronic
Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
whether Nilotinib at the two sequential dosage forms will induce quicker and deeper response in those patients, and if FISH on PB (Peripheral blood) would be an effective way to monitor response compared to conventional…
- Trial name
- NISRI (NCT02086487)
- Testing
- Nilotinib 300 mg.
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 98 people
- Sponsor
- King Abdullah International Medical Research Center
Chronyc Myeloid Leukemia
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia
The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the ELN criteria.
- Trial name
- SUSTRENIM (NCT02602314)
- Testing
- Imatinib, Nilotinib
- Where
- 82 sites in Italy, Netherlands
- Volunteers
- 450 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Sepsis, Fluid Overload
Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis
Sepsis is a common and life-threatening condition caused by a dysregulated host immune response to infection. Given the prominent role of endothelial breakdown and dysfunction in sepsis, therefore, there is an urgent need to…
- Conditions
- Sepsis, Fluid Overload, Endothelial Dysfunction, Microcirculation
- Trial name
- INITIALISE (NCT06626984)
- Testing
- Imatinib, Compound sodium lactate solution
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Belfast Health and Social Care Trust
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
The main goal of this study is to evaluate the stability of molecular response (major and deep molecular response( MMR and DMR)) in patients with chronic myeloid leukemia (CML) with stable DMR after two-stage dose reduction phase…
- Conditions
- Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia
- Trial name
- READIT (NCT04578847)
- Testing
- Imatinib, Nilotinib, Dasatinib
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Research Center for Hematology, Russia
Cancer, Breast Cancer
Role of Gene Variation in Effectiveness of Gleevec Treatment
This study will examine DNA from cancer patients previously treated with Gleevec to look for a variation (mutation) of the ABCG2 gene that may render the drug less effective in certain patients.
- Trial name
- NCT00342056
- Where
- 2 sites in United States, Belgium
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Chronic
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
This open-label, multicenter trial will evaluate the efficacy and safety of treatment with AMN107 in chronic myelogenous leukemia (CML) patients that are resistant and/or intolerant to imatinib mesylate therapy.
- Trial name
- NCT00264160
- Testing
- AMN107
- Where
- 4 sites in Israel
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia
Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
The study was performed to assess: 1) clinical activity of Imatinib in patients with HES, CEL and CIH; 2) correlation between Imatinib activity and specific disease subtype; 3) long-term outcome of HES, CEL and CIH patients…
- Conditions
- Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia, Chronic Idiopathic Hypereosinophilia
- Trial name
- NILG-HES1-03 (NCT00787384)
- Testing
- Imatinib
- Where
- 4 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Northern Italy Leukemia Group
Chronic Myeloid Leukemia
Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy
Standard therapy with Imatinib (IM) significantly prolongs the survival of Ph+CML patients who obtain a complete cytogenetic response (CCgR).
- Trial name
- INTERIM0407 (NCT00858806)
- Testing
- Imatinib
- Where
- Italy
- Volunteers
- 78 people
- Sponsor
- Università degli Studi di Brescia
Chronic Myeloid Leukemia
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment successfully.
- Trial name
- NCT04043676
- Testing
- Ponatinib
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fundación Teófilo Hernando, Spain
Chronic Myelogenous Leukemia, Short Stature
Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission
CML is a myeloproliferative disorder defined by the presence of the Philadelphia chromosome, which arises from the reciprocal translocation of genes on chromosomes 9 and 22.It is rare in childhood and accounts for 2-3% of all…
- Trial name
- NCT01901666
- Testing
- Growth Hormone
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
CML
Treatment Modification Based on Early Assessment of CML Patients
The investigators will check the feasibility of using early molecular response for making treatment decisions. Patients diagnosed with chronic myeloid leukemia will commence imatinib treatment.
- Trial name
- NCT01762969
- Testing
- Treatment modification based on molecular response at 3 months
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Rabin Medical Center
Leukemia
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
RATIONALE: Tyrosine kinase inhibitors may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00363649
- Testing
- GM-K562 cell vaccine, Interferon alfa, Sargramostim
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Myeloid, Chronic
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
The purpose of this study is to compare the efficacy of dasatinib with that of high-dose (800-mg) imatinib in participants with chronic phase chronic myeloid leukemia who achieved only a suboptimal response after at least 3…
- Trial name
- NCT00320190
- Testing
- Imatinib, Dasatinib
- Where
- 27 sites in Belgium, Finland and 9 more
- Volunteers
- 52 people
- Sponsor
- Bristol-Myers Squibb
Myelogenous Leukemia
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their Philadelphia chromosome-positive (Ph+) Chronic…
- Trial name
- ENEST (NCT00519090)
- Testing
- Imatinib, Nilotinib (AMN107)
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia
Nilotinib Plus Pegylated Interferon-α2b in CML
The purpose of this trial is to assess the effect of switching CML patients, who have been treated with imatinib ≥ 2 years and who have stable detectable molecular residual disease between 0.01-1.0% (IS), to the combination of…
- Trial name
- NCT01866553
- Testing
- Nilotinib, Pegylated interferon α-2b
- Where
- 5 sites in Denmark, Finland and 3 more
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Leukemia
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
The extension study followed the core study CAMN107ECN02 (NCT01275196). which is an open-label, two armed study. All patients enrolled in this extension study were able to benefit from the treatment given in CAMN107ECN02 per…
- Trial name
- NCT02272777
- Testing
- Imatinib, Nilotinib
- Where
- 12 sites in China
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Chronic, BCR-ABL Positive
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
The purpose of this study is to determine if low-dose imatinib and nilotinib combination, will improve treatment results in CML patients with failure, suboptimal response or intolerance to imatinib therapy.
- Trial name
- NCT01819389
- Testing
- Imatinib and Nilotinib
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Chronic Phase Chronic Myeloid Leukemia
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying…
- Trial name
- DASCERN (NCT01593254)
- Testing
- Imatinib, Dasatinib
- Where
- 101 sites in United States, Argentina and 13 more
- Volunteers
- 262 people
- Sponsor
- Bristol-Myers Squibb